Troubled Adamis To Merge With Private DMK, Focus On Neurological Disease

 
• By Joseph Haas

Deal Snapshot: Following a clinical failure for its COVID-19 candidate, Adamis sought strategic alternatives. DMK boasts a library of 750 first-in-class small molecule peptide analogues.

Merger
Adamis and DMK join the list of small biopharmas merging for financial reasons • Source: Shutterstock

More from Deals

More from Business